Allogeneic cord blood–derived NK cells are gene-modified to express an affinity‑enhanced TCR specific for the NY‑ESO‑1 peptide presented by HLA‑A*02, enabling antigen-specific recognition of NY‑ESO‑1–positive tumor cells. Upon engagement, the cells mediate cytotoxic killing via TCR-driven activation and NK effector mechanisms. Engineered autocrine IL‑15 secretion supports NK cell survival, proliferation, and persistence in vivo.